Polyclonal tuberculosis and the emergence of drug resistance

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 5, 2005, Pages 521-522

  Behr, Marcel A ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL DNA; CATALASE; GLYCOLIPID; ISONIAZID; PEROXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; EDITORIAL; HUMAN; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CLONE CELLS; DNA, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 24144457551     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2506008     Document Type: Editorial

References (13)

1. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Shinnick TM. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993;31:406-409.
2. Yeh RW, Hopewell PC, Daley CL. Simultaneous infection with two strains of Mycobacterium tuberculosis identified by restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 1999;3:537-539.
3. Warren RM, Victor TC, Streicher EM, Richardson M, Beyers N, van Pittius NCG, van Helden PD. Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med 2004;169:610-614.
4. Nguyen D, Brassard P, Menzies D, Thibert L, Warren R, Mostowy S, Behr M. Genomic characterization of an endemic Mycobacterium tuberculosis strain: evolutionary and epidemiologic implications. J Clin Microbiol 2004;42:2573-2580.
5. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, Enarson DA, Behr MA, van Helden PD. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005;171:1430-1435.
6. van Rie A, Victor TC, Richardson M, Johnson R, van der Spuy GD, Murray EJ, Beyers N, Gey van Pittius NC, van Helden PD, Warren RM. Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 2005;172:636-642.
7. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004;10:S122-S129.
8. Zhang Y, Heym B, Allen B, Young D, Cole ST. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:591-593.
9. Ng VH, Cox JS, Sousa AO, MacMicking JD, McKinney JD. Role of KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte oxidative burst. Mol Microbiol 2004;52:1291-1302.
10. Kato-Maeda M, Bifani PJ, Kreiswirth BN, Small PM. The nature and consequence of genetic variability within Mycobacterium tuberculosis. J Clin Invest 2001;107:533-537.
11. Reed MB, Domenech P, Manca C, Su H, Barczak AK, Kreiswirth BN, Kaplan G, Barry CE III. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 2004;431:84-87.
12. Tsenova L, Ellison E, Harbaeheuski R, Moreira AL, Kurepina N, Reed MB, Mathema B, Barry CE III, Kaplan G. Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis 2005;192:98-106.
13. Levin BR, Lipsitch M, Bonhoeffer S. Population biology, evolution, and infectious disease: convergence and synthesis. Science 1999;283:806-809.